NASDAQ · Biotechnology

MDXG (MDXG) Stock

$4.26 +1.43% NASDAQ: MDXG Healthcare

Valuation

MetricValue
Price$4.26
Market Cap$634.51M
P/E Ratio18.47
P/B Ratio2.13
P/S Ratio1.41
EPS (TTM)$0.32
52-Week High$7.99
52-Week Low$3.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE13.77%
ROA8.55%
ROCE24.90%
Gross Margin81.04%
Operating Margin10.17%
Net Margin7.88%
Debt/Equity0.01
Current Ratio4.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$242.0M$268.0M$321.0M$349.0M$419.0M
Operating Profit$-7.0M$-15.0M$37.0M$59.0M$64.0M
Net Profit$-12.0M$-30.0M$67.0M$42.0M$49.0M
EPS$-0.09$-0.27$0.38$0.28$0.32
Op Margin-2.9%-5.5%11.6%16.9%15.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$188.0M$171.0M$239.0M$264.0M$343.0M
Total Liabilities$95.0M$97.0M$96.0M$71.0M$86.0M
Cash$87.0M$66.0M$82.0M$104.0M$166.0M
Borrowings$53.0M$52.0M$48.0M$25.0M$23.0M

Latest News

MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut Simply Wall St. · Jun 20, 2026 How The MiMedx Group (MDXG) Story Is Shifting As Analysts Rework Price Targets Simply Wall St. · Jun 6, 2026 MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference GlobeNewswire · May 21, 2026 Is the Options Market Predicting a Spike in MiMedx Group Stock? Zacks · May 11, 2026 MiMedx Launches G4Derm Plus Wound-Care Product Across US MT Newswires · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-18.0M$27.0M$66.0M$74.0M
Investing Cash Flow$-7.0M$-4.0M$-4.0M$-11.0M$-8.0M
Financing Cash Flow$-3.0M$-1.0M$-10.0M$-2.0M$-4.0M
Net Cash Flow$-9.0M$-21.0M$16.0M$22.0M$62.0M
Free Cash Flow$-5.0M$-19.0M$25.0M$65.0M$73.0M

Valuation & Return Ratios

MetricValue
PEG Ratio2.88
EV / EBITDA7.45
FCF Yield11.92%
Quick Ratio4.81
Interest Coverage32.00
Return 1Y-40.40%
Return 3Y-44.64%
Return 5Y-63.06%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
CVACCureVac N.V. $4.66 +0.00% 5.69 $1.05B 0.00%
DNTH $104.09 +2.44% -17.99 $4.35B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
INVA $20.51 -2.84% 3.60 $1.51B 0.00%

About MDXG

MDXG is led by CEO Joseph H. Capper, employs 837 people, headquartered in US, publicly traded since 2008.

MDXG stock trades at $4.26 with a market capitalization of $634.51M. The stock is valued at a price-to-earnings (P/E) ratio of 18.47, price-to-book of 2.13, price-to-sales of 1.41. Over the past 52 weeks the stock has ranged between $3.03 and $7.99, and currently trades 46.7% below its 52-week high.

On profitability, MDXG generates a return on equity (ROE) of 13.77%, above the typical market average, return on capital employed of 24.90%, an operating margin of 10.17%, a net profit margin of 7.88%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides